PEG-Protein Conjugate Stability and Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Proteins used in therapeutics often face challenges such as susceptibility to proteolytic degradation, short half-life, low water solubility, and immunogenicity, which hinder their effectiveness in treating diseases like idiopathic myelofibrosis, polycythaemia vera, and essential thrombocythaemia.
Innovation Solution
A protein-polymer conjugate is developed, specifically combining a 20 kD molecular weight polyethylene glycol (PEG) with an interferon-α2b moiety, enhancing protein stability, solubility, and reducing immunogenicity, which is synthesized through known chemical methods and purified to high purity for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a polymer is attached to a protein, then protein stability and water solubility are improved, but the complexity of the conjugate increases
Solution Approach 1:
A polymer intermediary (polyethylene glycol or polypropylene oxide) is introduced between the proteolytic enzyme and the protein backbone, physically blocking enzyme access while maintaining protein structure and function. This mediator approach resolves the contradiction by providing stability without requiring complex structural modifications to the protein itself.
Solution Approach 2:
The invention creates a composite material system combining polymer and protein components with defined molecular weights and stoichiometric ratios. This composite approach allows optimization of stability while controlling complexity through systematic variation of polymer-to-protein ratios and polymer molecular weights.
2Object-affected harmful factors
If a polymer is attached to a protein, then immunogenicity is reduced, but the manufacturing complexity increases
Solution Approach 1:
The invention systematically varies critical parameters including polymer molecular weight (2-100 kD range), protein molecular weight, and polymer-to-protein stoichiometric ratios to optimize immunogenicity reduction. This parameter optimization approach allows finding the simplest effective formulation that minimizes immunogenicity while maintaining manufacturability.
3Stability of the object's composition
If the polymer molecular weight is increased, then protein stability is enhanced, but the half-life of the conjugate may be reduced
Solution Approach 1:
The invention optimizes polymer molecular weight within a specific range (2-100 kD) to balance two competing effects: sufficient polymer size to block proteolytic enzymes and provide stability, versus maintaining appropriate hydrodynamic radius and circulation characteristics. This parameter optimization resolves the contradiction by identifying the optimal polymer size window.
Solution Approach 2:
The invention uses a partial action approach where the polymer attachment provides sufficient but not excessive protection. By using moderate polymer molecular weights and optimized attachment stoichiometry, the conjugate achieves adequate proteolytic protection while avoiding excessive size that would reduce circulation half-life and renal clearance efficiency.
Data Source
AI summary
This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia..